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Background: Impaired hemopoiesis is common following renal transplantation
managed using mTOR inhibitors. The mechanisms responsible are uncertain but include
direct effects on iron, hepcidin or erythropoietin-mediated hemopoiesis.
Methods: We conducted a single center prospective case-control study of 26 adult RTR
with stable allograft function. RTR received stable mTOR dosing (cases, 11/26 [42%])
or stable tacrolimus dosing (controls, 15/26 [58%]). Baseline demographics, full blood
count, renal function, iron studies, hepcidin-25, Interleukin-6 (IL-6) and erythropoietin
(EPO) levels were determined.
Results: There were no differences in age, gender or allograft function. Mean daily
sirolimus dose for cases was 1.72 mg, with mean trough level of 8.46 ng/mL. Mean daily
tacrolimus dose for controls was 4.3 mg, with mean trough level of 5.8 ng/mL. There were
no differences in mean hemoglobin (143 vs. 147 g/L; p = 0.59), MCV (88 vs. 90 fL; p =
0.35), serum ferritin (150 vs. 85.7 µg/L; p = 0.06), transferrin saturation (26 vs. 23.3%;
p = 0.46), IL-6 (11 vs. 7.02 pg/ml; p = 0.14) or hepcidin-25 (3.62 vs. 3.26 nM; p =
0.76) between the groups. EPO levels were significantly higher in the group receiving
mTOR therapy (16.8 vs. 8.49 IU/L; p = 0.028). On logistic regression analysis EPO
level was the only variable that had a significant impact providing an odds ratio of 0.84
(95%CI 0.66–0.98). The area under the receiver operator characteristic curve (ROC) for
the analysis was 0.77 (95%CI 0.54–0.94) with p = 0.04.
Conclusion: Higher levels of EPO in the absence of deranged iron biochemistry or
hepcidin-25 levels suggest that EPO resistance rather than impaired iron metabolism
may contribute to the impaired hemopoiesis previously demonstrated in RTR on
mTOR therapy.
Keywords: renal transplant, mTOR inhibitor, anemia, iron deficiency, hepcidin, erythropoietin, erythropoietin
resistance
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INTRODUCTION

care, except hepcidin, EPO and IL-6 assays which were
not routine.

Anemia occurs in 13–70% of individuals (1–3) following
renal transplantation. Potential contributors to anemia include
impaired graft function, drugs, inflammation, infection, iron
deficiency and rejection. Mammalian target of rapamycin
(mTOR) inhibitors have been shown to impair haemopoiesis and
cause microcytosis (4, 5). The anti-proliferative effect of this class
of drugs is evidenced by the leukopenia and thrombocytopenia
associated with their use (6). The mechanism by which mTOR
inhibitors exert their effects on red blood cells is uncertain.
Thanaut et al. suggested that sirolimus induced anemia (SIA) is
most likely due to an inflammatory state (7), plausible on the
basis of the known effects of inflammation on iron bioavailability
and hepcidin production. Hepcidin is a 25 amino acid peptide,
produced by hepatocytes, and which acts as a negative regulator
of iron release from cells by binding to ferroportin, resulting
in its internalization and degradation (8). Hepcidin gene
inactivation results in iron overload (9) whilst over-expression
results in severe iron deficiency anemia (10). Inflammation can
increase hepcidin levels, primarily mediated through increased
production of interleukin 6 (IL-6), which binds to the gp130
protein receptor complex causing phosphorylation of signal
transducer and activation of transcription 3 (STAT3) which then
promotes hepcidin transcription (11, 12). Other studies suggest
that SIA is independent of drug anti-proliferative effects and
that iron homeostasis maybe directly affected by sirolimus as
opposed to the development of an inflammatory state (13). A
final mechanism proposes the development of erythropoietin
(EPO) resistance induced by mTOR inhibitors as a potential
cause of SIA (14–16).
The aim of our study was to elucidate the role of
mTOR inhibitors on iron, hepcidin and erythropoietinmediated regulation of hemopoiesis in stable renal transplant
recipients (RTR).

Data Collection
Baseline demographic data were collected from electronic
health records and included age, gender, type of transplant,
reason for transplant, years since transplant, immunosuppressive
regimen with total daily dose and reason for use of mTOR
inhibitor. Co-morbidities and reasons for an active inflammatory
state were also recorded. No cases or controls received
iron or erythropoietin supplementation in the preceding
12 months.
The preferred maintenance immunosuppression postrenal transplant at our institution is triple therapy with
prednisolone, tacrolimus and mycophenolate mofetil
(MMF). Non-melanoma skin cancers and early allograft
nephropathy are the most common reasons for switching
tacrolimus to an mTOR inhibitor. 7/11 (64%) cases were
using mTOR inhibitors due to non-melanoma skin cancers,
with 2 of these 7 also having a history of additional solid
organ malignancies. The remaining 4/11 (36%) were using
mTOR inhibitors due to early allograft nephropathy with
calcineurin inhibitors. Immunosuppressive regimens were
variable for cases; 7/11 (64%) patients were on three agents
(prednisolone, MMF and mTOR inhibitor for most), 2/11
(18%) were on two agents (mTOR inhibitor plus prednisolone
or MMF) and 2/11 (18%) were on sirolimus monotherapy.
Immunosuppressive regimens for controls consisted of three
agents for 12/15 (80%) whilst 3/15 (20%) were on prednisolone
and tacrolimus only.
Laboratory data included hemoglobin (Hb), mean cell
volume (MCV), iron studies (serum iron, ferritin, transferrin
and Tsats), creatinine, eGFR, hepcidin-25, EPO and IL-6
levels. eGFR was calculated using the CKD-EPI equation
at our institution (17), a reported eGFR >90 ml/min was
entered as 90 ml/min for the purpose of data tabulation.
All laboratory data for each individual patient were from the
same venepuncture.
Serum IL-6 levels were measured by ELISA according to the
manufacturer’s instructions (Human IL-6 Quantikine HS ELISA
kit, R&D Systems, Inc. Minneapolis, USA). The assay had a
sensitivity of 0.039 pg/mL (18).
Hepcidin was isolated from serum using a solid phase
extraction approach, and measured by liquid chromatographyquadrupole time-of-flight mass spectrometry (LC-qTOF-MS),
using a Waters Xevo XS Mass Spectrometer (Waters, Manchester,
UK). Quantitation of the hepcidin was by measurement of the
accurate mass [M+5H]5+ ion, against a synthetic hepcidin-25
heavy isotope standard (Peptides International, Kentucky, USA)
as previously described (19–21).

METHODS
Study Design and Patient Selection
We conducted a single-center, prospective case-control study
of 26 adult RTR conducted between 2016 and 2019. RTR
were on stable mTOR inhibitor (cases, 11/26 [42%]) or
tacrolimus dosing (controls, 15/26 [58%]). Patients were
recruited opportunistically through routine follow-up clinics
following renal transplant. Inclusion criteria for cases were: age
>18 years, >1 year post renal transplant on either sirolimus
or everolimus, estimated glomerular filtration rate (eGFR) >45
ml/min and no evidence of biopsy proven rejection in the
preceding 12 months. Controls received tacrolimus instead
of an mTOR inhibitor. Exclusion criteria were: age <18 or
>80 years, other causes of anemia such as gastrointestinal
bleeding and the presence of active non-skin malignancies. The
study was approved by the South Metropolitan Health Service
Human Research Ethics Committee and all patients provided
written informed consent before participation. Laboratory tests
for the study were conducted as part of routine clinical
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Statistical Analysis
Data are presented as mean and median values, with standard
deviation (SD) and interquartile range (IQR), as appropriate.
Case and control data passed normality testing using
Anderson-Darling and D’Agostino-Pearson tests. Groups were
compared using unpaired t-tests and results were considered
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TABLE 1 | Characteristics of RTR subjects included in study.
mTOR inhibitor based regimen
Male
Gender
Type of transplant

Tacrolimus based regimen

Female

Male

p-value

Female

6

5

8

7

Cadaveric

Live

Cadaveric

Live

4

7

8

7

Mean

Median

SD

IQR

Mean

Median

SD

IQR

Age (years)

54

59

15.3

30

49

52

12.4

14

0.37

eGFR
(mL/min/1.73 m2 )

69

62

14.8

34

73

77

18.4

25

0.55

Years
post-transplant

9

8

4.9

4

3.5

2

2.7

5

<0.001

significant if the p-value was <0.05. Logistic regression analysis
was performed (Prism 9.1, GraphPad Software).

TABLE 2 | Details of mTOR inhibitor and tacrolimus use.
Everolimus
based
regimen

No. of subjects

9

2

15

Mean daily dose
(mg)

1.72

1

4.3

Mean trough level
(ng/mL)

8.46

2.2

5.8

RESULTS
Patient Population
There were no differences between cases and controls in terms
of age, gender or allograft function (Table 1). Characteristics of
renal transplants in each group are described in Table 1. Details
of mTOR inhibitor and tacrolimus use, including daily doses
and mean trough levels, is summarized in Table 2. Cases were
significantly longer post-transplant than controls (9 vs. 3 years; p
= 0.001).
Two cases had underlying inflammatory states; one had
chronic Mycobacterium avium complex infection on therapy and
a second had colitis 1 week prior to venepuncture.

observed that those receiving mTOR inhibitors had higher
levels of EPO, suggesting that EPO resistance is induced by
mTOR inhibitor treatment. In both groups eGFR was maintained
suggesting elevated EPO was not explained by declining
renal function. In our study, the elevated EPO production
was able to compensate and preserve hemopoiesis. Previous
studies have demonstrated that microcytosis or anemia are
induced in mTOR inhibitor-treated subjects (7, 13–15, 22–
24). EPO is also known to inhibit hepcidin production (25–
28). The presence of similar hepcidin levels in the mTOR
and tacrolimus groups, despite the elevated EPO levels in
the former, suggests that the effects of EPO are probably
direct and not mediated via changes in hepcidin production.
In vitro studies have demonstrated that mTOR inhibitors
induce microcytosis, possibly due to inhibition of erythroid
precursors (22, 23) and that these effects are not overcome by
increasing available iron in the culture environment (23). This
microcytosis is reversed by withdrawal of mTOR inhibitors (7,
13, 15).
Chronic inflammation has been implicated in the causation
of microcytic anemia secondary to sirolimus. Thanaut et al.
observed elevations in ferritin and CRP in patients on sirolimus
which fell after withdrawal of the drug (7). A subset analysis
in the same study demonstrated elevated IL-6 and TNF∝
measurements that fell with sirolimus withdrawal in six patients.
Sirolimus trough levels were higher than those seen in our
study. Przybylowski et al. reported elevated hepcidin and IL6 levels in orthotopic heart transplant patients treated with
mTOR inhibitors and suggested that chronic inflammation

Red Blood Cell Indices, Iron Studies,
Hepcidin, and IL-6
The mean Hb and MCV levels for both cases and controls
were within the reference range and there were no significant
differences between the two groups (Table 3). There were no
significant differences for serum ferritin, transferrin saturation,
hepcidin-25 or IL-6 levels between the two groups (Tables 3, 4).
The mean EPO levels were significantly higher in the mTOR
inhibitor group compared with controls (16.8 vs. 8.49 IU/L, p
= 0.028). A logistic regression analysis was performed using
mTOR use (yes/no), Hb and EPO levels as the variables. EPO
level was the only variable that had a significant impact on the
model providing an odds ratio of 0.84 (95%CI 0.66–0.98). The
area under the receiver operator characteristic curve (ROC) for
the analysis was 0.77 (95%CI 0.54–0.94) with p = 0.04.

DISCUSSION
Several mechanisms have been suggested to underly the impaired
hemopoiesis observed in RTR receiving mTOR inhibitor
therapy. These include inflammation, impaired iron or hepcidin
metabolism, and dysregulated erythropoietin metabolism. Whilst
subjects in our study receiving mTOR inhibitor or tacrolimus
therapy had similar hematologic parameters, serum iron
biochemistry, renal function, hepcidin and IL-6 levels, we
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Tacrolimus
based
regimen

Sirolimus based
regimen
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TABLE 3 | Red blood cell indices and iron study parameters.
mTOR inhibitor based regimen
Mean

Median

SD

Hb (g/L)

143

142

19.5

MCV (fL)

88

87

6.9

Tacrolimus based regimen
IQR

p-value

Mean

Median

SD

IQR

30

147

142.5

19.6

21

0.59

10

90.4

90

5.9

3

0.35

Ferritin (µg/L)

150

116

111

162

85.7

73.5

53.9

90.4

0.06

Transferrin

27.3

29.2

5.6

9.9

31

30.5

5.1

8.4

0.09

Tsats (%)

26

26

7.6

13

23.3

23

9.8

17

0.46

TABLE 4 | EPO, hepcidin and IL-6 levels.
mTOR inhibitor based regimen
Mean

Median

Tacrolimus based regimen

SD

IQR

Mean

Median

SD

p-value
IQR

EPO (IU/L)

16.8

11.8

13.1

9.6

8.49

8.5

3.94

5.2

0.028

Hepcidin-25 (nM)

3.62

3.20

2.84

2

3.26

2.6

2.89

4.8

0.76

11

8.5

6.4

7.65

7.02

5.11

6.65

4.7

0.14

IL-6 (pg/mL)

to MMF (erythropoietin:Hb ratio 2.7 on sirolimus, to 1.2 on
MMF (where Hb was measured in g/dL) (14). Our study confirms
and extends the observations of Augustine et al., demonstrating
elevated EPO levels in the mTOR inhibitor group with similar Hb
to the tacrolimus group.
Our study is limited by the small sample size in both our cases
and controls and the variable use of sirolimus and everolimus
in our cases. The different immunosuppressive regimens used
in each group and the two cases of active inflammation in our
mTOR inhibitor group are potentially confounding variables
that reflect real-world practice with these complex patients. The
absence of anemia and microcytosis in this cohort requires
these results to be extrapolated to be applied to this cohort
as an explanation for this phenomenon. This may have been
due to sample size, duration of drug exposure or the target
levels achieved being below a threshold for effect. Cases were
significantly longer post-transplant than controls which may
have influenced results, however, this did not result in a
differences in age or allograft function.
In conclusion, higher levels of EPO in the absence of
deranged iron biochemistry or hepcidin-25 levels suggest that
EPO resistance rather than impaired iron metabolism may
contribute to impaired haemopoiesis previously demonstrated in
RTR on mTOR therapy.

and increased hepcidin production may be responsible for
functional iron deficiency in these patients (29). This study had
significant confounding variables, including older age, lower
eGFR and higher BNP levels in mTOR inhibitor group. A
prospective randomized study by Maiorano et al. produced
results consistent with our observations, demonstrating that
prohepcidin levels were similar in patients on sirolimus
vs. cyclosporin, despite the presence of microcytic anemia
in the sirolimus patients, which was not improved with
oral iron supplementation (13). However, prohepcidin levels
correlate poorly with total body iron status in comparison
with mature hepcidin-25 (30). A 2021 pediatric case-control
study found no difference in IL-6, hepcidin or ferritin levels
in 17 children with tuberous sclerosis complex treated with
everolimus compared to 47 controls (23). IL-6 levels were
also measured in the patients prior to commencing everolimus
and at 3, 6 and 12 months with no significant elevation
with introduction of everolimus (23). IL-6 levels were similarly
elevated in both our treatment groups, compared to data
derived from healthy adults (31), indicating similar levels of
inflammation and suggesting this pathway does not contribute
to impaired hemopoiesis.
mTOR inhibitors have been shown to inhibit the EPO
signaling pathway at the level of EPO receptor signaling (32).
In the presence of EPO, the EPO receptor activates multiple
phosphorylating enzymes, including phosphoinositide 3-kinase
(PI 3-K) which leads to eventual activation of P70S6 kinase with
subsequent protein synthesis and cell proliferation (32). mTOR
inhibitors are potent inhibitors of P70S6 kinase (33–35). This
direct effect on the EPO pathway may explain the previously
demonstrated effect of mTOR inhibitors on red cell indices that
are disproportionate to their effects on other aspects of bone
marrow function. Augustine et al. provided data in support of
mTOR inhibitor-induced EPO resistance, demonstrating a fall in
EPO resistance when switching 25 stable RTR from sirolimus
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